MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Myriad Genetics Inc. (MYGN) is not a strong buy for a beginner, long-term investor at this time. The stock is currently in a bearish technical trend with no significant positive catalysts or trading signals to suggest immediate upside potential. Given the investor's preference for long-term growth, it would be prudent to wait for clearer signs of recovery or improved fundamentals before considering an investment.
The stock is in a bearish trend with the MACD below zero and negatively contracting, indicating downward momentum. The RSI is at 9.038, signaling an oversold condition, but this alone does not confirm a reversal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 4.369, with resistance at 5.217.
The company published validation results for its FirstGene Multiple Prenatal Screen, demonstrating high sensitivity and specificity, which could enhance its product credibility in the prenatal screening market.
Revenue declined by 3.56% YoY in Q3 2025, and gross margin dropped slightly. The upcoming earnings call on February 23, 2026, could reveal further financial challenges. Analysts have lowered the price target to $7, reflecting cautious sentiment.
In Q3 2025, revenue decreased to $205.7M (-3.56% YoY), while net income improved to -$27.4M (+23.98% YoY). EPS improved to -0.29 (+20.83% YoY), but the company remains unprofitable. Gross margin slightly declined to 69.91% (-0.46% YoY).
TD Cowen recently lowered the price target from $9 to $7 and maintained a Hold rating, citing solid fundamentals for the diagnostics sector but a cautious outlook for the company.
